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ABSTRACT
In 2011, a field trial was conducted in southeastern West Virginia to evaluate the safety and
immunogenicity of a live recombinant human adenovirus (serotype 5)-rabies glycoprotein
vaccine (ONRAB®) in wild raccoons and skunks. ONRAB® was selected for evaluation based on
the success achieved in eliminating raccoon rabies from Ontario and Quebec, Canada, through
the integration of this vaccine into rabies management strategies and significantly higher seropositivity in comparison to Raboral V-RG® in studies along the U.S.-Canada border. The field
trial site was composed of forested and agricultural habitats in an area where raccoon rabies is
enzootic and oral rabies vaccine (ORV) has never been used as a management strategy. The
ULTRALITE bait is composed of a small blister pack that contains the ONRAB® vaccine with a
waxy coating matrix of sweet attractants, impregnated with tetracycline biomarker, camouflaged
by a khaki green dye. Approximately 80,000 baits were distributed at 75 baits/km2 mostly by
fixed wing aircraft along parallel flight lines spaced at 750 m intervals. There were no phone
calls related to human or pet bait contacts reported through the affixed, legible toll free phone
number on each bait. Relatively low human population density in the study area and bait
attributes that may make them less attractive to dogs could have been contributing factors
resulting in no reported bait contacts. Histopathology results from up to 23 tissue types from
diverse target and nontarget wildlife species samples pre (n=290) and post-ORV (n=300) with
ONRAB® will be provided under a separate cover once the analysis is completed. No differences
were observed between control and treatment captive animals, including cottontail rabbit
(Sylvilagus floridanus), opossum (Didelphis virginiana), fox squirrel (Sciurus niger), and eastern
wild turkey (Meleagris gallopavo silvestri) that received a 10x ONRAB® dose in a companion
histopathology study conducted at the Wildlife Services (WS), National Wildlife Research
Center. These species that have not been previously evaluated for potential ONRAB® effects are
common to the West Virginia field trial site. The proportion of raccoons categorized as seropositive was significantly higher in (P< 0.05) the post-ORV ONRAB® baiting period (49.4%,
n=296) in comparison to the pre-ORV (9.6%, n=395)) period (naïve to ORV either with
ONRAB® or Raboral V-RG® but where raccoon rabies is enzootic). The 49.4% sero-positivity in
raccoons was the highest observed by WS for areas with similar management histories that were
baited once at 75 baits/km2 with Raboral V-RG®. Biomarker presence was significantly
(P<0.05) higher among sero-positive raccoons post-ORV and similar (P>0.05) among raccoons
during the pre-ORV period, an indication of vaccine-induced rabies virus neutralizing antibodies
(RVNA) following bait consumption. Skunk sample size was inadequate to assess ONRAB®
effects, but other studies have not shown a strong RVNA response at 75 baits/km2. Overall, the
safety and immunogenicity outcomes from this field trial support replicating the West Virginia
field trial to determine if raccoon population immunity would increase as a function of a second
annual ORV campaign with ONRAB®. Expansion of field trials into other strategic areas such as
the Ohio contingency action zone, the Niagara Frontier and along the Quebec border with New
York, Vermont and New Hampshire is recommended.
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INTRODUCTION
In 2011, APHIS, Wildlife Services (WS) coordinated a collaborative oral rabies vaccine field
trial to evaluate the safety and immunogenicity of ONRAB® (Artemis Technologies, Guelph,
Ontario, Canada) in raccoons and skunks in West Virginia (Appendix A). It was the first field
trial of this type in the U.S. in over 20 years (Roscoe et al. 1998). This field trial was conducted
to evaluate a vaccine that has the potential to be licensed and applied strategically to more
aggressively meet raccoon rabies management goals, including elimination. ONRAB® is a live
recombinant vaccine that uses human adenovirus (serotype 5) to express the rabies virus
glycoprotein gene (Charlton et al., 1992). Over 6 million doses of ONRAB® have been
distributed in Ontario since 2006 for skunk and raccoon rabies control (D. Donovan, personal
communication) and Quebec since 2007 for raccoon rabies control (J. Mainguy, personal
communication). Both Provinces appear to have eliminated raccoon rabies virus variant through
the integration of ONRAB® into broader rabies control strategies (Rosatte et al. 2009a, Rees et
al. 2011).
Highly collaborative processes were put in place to meet regulatory, technical, environmental
and logistical demands associated with the vaccine-bait field trial conducted in West Virginia.
Collaborators included county, state, federal and international partners from government and
non-government organizations, as well as Artemis Technologies, ONRAB® manufacturer (Table
1). Artemis Technologies was responsible for providing the requisite data to APHIS, Veterinary
Services, Center for Veterinary Biologics (CVB), with formal public health input from CDC to
facilitate a comprehensive ONRAB® risk assessment. Published information on ONRAB® and
data on file were also part of the foundation for a WS Environmental Assessment that evaluated
the potential impacts of releasing this vaccine into the wild in West Virginia. A joint CVB and
WS Federal Register Notice was issued to notify the public of plans for an ONRAB® field trial
and to solicit input and comments (U. S. Department of Agriculture, 2011a).
This report covers key aspects and findings of the ONRAB® field trial and provides
recommendations for future field evaluations.
BRIEF BACKGROUND
The concept of oral rabies vaccination (ORV) to control rabies in free-ranging wildlife originated
in the U.S. (Baer et al., 1971; Baer, 1988). ORV has been widely used in Europe beginning in
the late 1970’s and Canada in the late 1980’s with success in controlling and eliminating rabies
in foxes from several European countries (Blancou, 2008; Wandeler, 2008) and all but a few
residual foci of an arctic variant of rabies in skunks in Ontario (Nadin-Davis et al., 2006; Rosatte
et al., 2011), as well as raccoon rabies from Ontario (Rosatte et al., 2009b) and Quebec (Rees et
al., 2011)(no cases since 2009). The rapid spread of raccoon rabies along the eastern seaboard of
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the U.S. and west to eastern Ohio as the probable result of translocations from Florida to Virginia
and West Virginia during the 1970’s (Nettles et al., 1979) served as a major stimulus for
intervention with ORV to prevent raccoon rabies from gaining an even broader geographic
footprint in the U.S.
Due to the risk, albeit it low, of vaccine-induced rabies associated with residual pathogenicity in
the Evelyn Rockitnicki Abelseth (ERA) strain of attenuated rabies virus (Fehlner-Gradiner et al.,
2008), a live recombinant Vaccinia-rabies glycoprotein (V-RG) vaccine became the prime
candidate for testing in the U.S. (Rupprecht et al., 1986). This vaccine cannot cause rabies,
although low levels of risk may be associated with exposure to the virus vector (Roess et al.,
2012). However, V-RG proved to be safe in more than 50 vertebrate species (Artois et al., 1990;
Rupprecht et al., 1992a; Rupprecht et al., 1992b). As a result of field safety and immunogenicity
testing in the early 1990s (Hanlon et al., 1998; Hanlon and Rupprecht, 1998; Roscoe et al.,
1998), V-RG was conditionally licensed in 1995, and fully licensed in1997, in the U.S. for
vaccination of free-ranging raccoons by Merial Ltd., Athens, Georgia under the registered name
Raboral V-RG®. It was also fully licensed in 2002 for coyotes in the U.S. and for raccoons in
Canada (Rosatte et al., 2001). It has been approved for experimental use in wild gray foxes and
has been used for this purpose in Arizona, New Mexico, and Texas (J. Maki, personal
communication). Raboral V-RG® currently remains the only licensed oral rabies vaccine for use
in the U.S.
Following the first field trial with V-RG in 1990, the number of vaccine-laden baits distributed
annually in the U.S. rose exponentially through 2006, but has decreased to about 8 million baits
in 2011 due to implementation of efficiencies such as consistency in ORV zone width throughout
most areas and 750m flight line spacing, as well as level WS funding for rabies management
(Figure 1). Since WS involvement in rabies management, APHIS has contributed about 120
million Raboral V-RG® baits for distribution in the U.S. between 1995 and 2010 (U.S.
Department of Agriculture, 2012). More than 75% of those baits have been used in campaigns to
prevent the spread of raccoon rabies beyond the eastern U.S. (Figure 2) and the remainder has
been applied in Texas, New Mexico and Arizona for rabies control and elimination efforts in
coyotes and gray foxes (U.S. Department of Agriculture, 2008; U.S. Department of Agriculture,
2009; U.S. Department of Agriculture, 2010a).
Coordinated ORV with Raboral V-RG® has resulted in three major rabies management
accomplishments in the U.S. Canine rabies from sources in Mexico, which had spilled over and
spread among coyotes in south Texas, has been eliminated through the integration of ORV into
conventional rabies prevention and control programs (Fearneyhough et al., 1998; Sidwa et al.,
2005). This success led to the U.S. being declared canine rabies free in 2008 (Velasco-Villa et
al., 2008). ORV has also been successfully applied to control a unique variant of gray fox rabies
in western Texas, with no reported cases since May 2009 (Blanton et al., 2011). Intervention
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with ORV beginning in 1997 has also prevented appreciable spread of raccoon rabies from its
new-found stronghold in the eastern U.S. (Slate et al., 2009).
These accomplishments are noteworthy, yet the inability to eliminate raccoon rabies in high risk
spread corridors has prompted the need to evaluate vaccines that may be capable of producing
higher levels of population immunity to achieve this programmatic goal. Ideally, vaccines
deemed safe, inexpensive and immunogenic in all meso-carnivore rabies reservoir species under
field conditions are desired. To date, little RVNA response has been observed among skunks
captured from ORV zones established with Raboral V-RG® to raccoon rabies control (Slate et al.,
2009). WS and collaborators identified the need to test new vaccine-baits as a priority in the
Vaccine/ Bait/Biomarker Team as part of discussions at the annual WS National Rabies
Management Team meeting during the past decade. In addition, a comprehensive review of the
WS, National Rabies Management Program recommended that new or improved vaccine-baits
be brought on line as swiftly as possible to better ensure program sustainability and success (U.S.
Department of Agriculture, 2010b).
After considering four candidate vaccines (Table 2), WS and collaborators decided to pursue a
field trial with ONRAB® in 2011. That decision was largely based on extensive use of ONRAB®
in Ontario and Quebec along the U.S border without untoward events and success in reducing
and eliminating raccoon rabies. Other contributing factors included the inability to access other
candidate vaccines for field testing in a timely fashion. Also, no skunks infected with the
raccoon rabies virus variant have emerged in Ontario since 2004, or Quebec since 2009,
suggesting that the occurrence of skunks infected with raccoon rabies is dependent on spillover
from the raccoon reservoir. In addition, under operational rabies control strategies using high
ORV bait densities (300 baits/km2) and narrow flight lines (250m), meaningful levels of
immunity have been achieved in skunk populations in an attempt to eliminate residual foci of an
arctic rabies variant from Ontario (Rosatte et al., 2011). While these bait densities would not be
sustainable at the landscape level, perhaps bait modifications could enhance future performance
of ONRAB® in skunks at lower bait densities.
ONRAB® uses a human adenovirus type 5 (HAd5) as a vector to express the rabies virus
glycoprotein gene. The virus vector has a well-characterized molecular structure, genomic
stability, and possesses the ability to grow high titers in a wide spectrum of cells (Graham and
Prevec, 1992). Each ONRAB® bait contains 1.8 ±0.1 ml of HAd5 ONRAB® vaccine (titer of not
<109.5 cell culture infectious dose 50%[CCID50]/ml) in an elongated plastic blister pack coated
with an attractant-bait matrix (Figure 3).The matrix is composed of partially hydrogenated
vegetable shortening (34%), Microbond® wax (International Wax Ltd., Agincourt, Ontario,
Canada) (30%), stearine (12.5%), icingsugar (20%), vegetable oil (1%), artificial marshmallow
flavor (1%), artificial sweet flavor (1%), and a fat-soluble food dye (0.5% khaki green) to
camouflage the baits. Each vaccine-bait weighs approximately 4 g. The body of the blister pack
is an elongated oval with dimensions of 1.81 x 0.55 x 0.39 in (30 x 14 x 10 mm) and a
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rectangular lip extending to 1.57 x 0.79 in (40x20 mm) (Figure 3). The blister pack contains an
identifying label as to the contents of the bait and a toll-free phone number where people can
obtain information about the baits (Rosatte et al., 2009a).
The ONRAB® bait matrix also can deliver 100 mg of tetracycline hydrochloride as a biomarker
to aid in evaluating bait ingestion. Tetracycline deposits in metabolically active portions of bones
and teeth of animals, which can be viewed in slide preparations under fluorescent light
microscopy. Tetracycline-positive tooth or bone indicates the likelihood that an animal has eaten
at least one bait (Johnston and Voight, 1982; Rupprecht et al., 1987; Rosatte et al., 2009a). The
presence of tetracycline does not equate to immunity because it is possible for an animal to eat
the outer bait matrix without rupturing the blister pack, resulting in no oral exposure to the
vaccine. Potential sources of "background" tetracycline may include consumption of medicated
feeds such as those sometimes used for production animals, intentional treatment by humans
with tetracycline, and non-specific fluorescence that may be found naturally (Chopra and
Roberts, 2001).
FIELD TRIAL DESIGN
The ONRAB® ORV zone was 1,460 km2 composed of hardwood and mixed coniferoushardwood forest, interspersed with livestock agriculture and small towns (U.S. Department of
Agriculture, 2011a). The spatial field trial design contained four 127 km2 sampling cells,
separated from each other by a 5 km buffer (Figure 2). The distance from the western edge of
the ONRAB® sampling cells to the existing ORV zone baited at 75 baits/km2 since 2001 (U.S.
Department of Agriculture 2005) with Raboral V-RG® was 11km. The buffer was provided to
reduce the chance of confounded serological results. The distance from the edges of the sampling
cells and the outer perimeter of ONRAB® baited area was 5 km to reduce dilution effect from
raccoon home ranges that may overlap from ONRAB® naive areas, where raccoons and skunks
would not have had equal opportunity to consume baits as compared to animals with home
ranges totally within the ONRAB® zone. A total of 79,027 ONRAB® baits with tetracycline
biomarker in the bait matrix were distributed within the field trial zone, with 77,448 baits aerially
distributed along parallel flight lines at a 750 m spacing. A total of 1,580 ONRAB® baits were
distributed through ground baiting in the vicinity of towns in the field trial zone where aerial
baiting could present a safety concern.
MATERIALS AND METHODS
The pre and post ONRAB® sampling profile for assessing safety and immunogenicity of
ONRAB® at 75 baits/km2 is summarized in Table 3.
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Animal Sampling
Target species biological and serological sampling
Animal sampling included live (cage) trapping (Tomahawk model 608) and release of target
species that were apparently not rabid based on behavior and gross examination for lesions.
Suspect animals were tested for rabies using a direct rapid immunohistochemistry test (dRIT),
with diagnostic confirmation and rabies virus variant typing performed at CDC. Non-target
species were either released or included among the required samples for histopathological
analysis. The same trapping approach was applied for pre and post-ONRAB® sampling.
About 150 live traps were set within 800 m of 25 preselected random points in each sampling
cell to ensure adequate spatial coverage (Figure 4). The same random points were used both pre
and post-ORV ONRAB® sampling periods, which were August 2-26, 2011 and September 2131, respectively. Traps were checked once every 24 hours. All rabies reservoir species captured
during pre and post-ORV with ONRAB® were anesthetized using an IM injection of a 5:1
mixture of ketamine and xylazine (Kreeger, 1999) so that blood as well as first premolar tooth
samples could be collected for aging and biomarker presence, and other pertinent biological
information such as sex, reproductive status, and the general condition of each animal. Serum
samples were collected from blood centrifuged the same day of capture, with aliquots briefly
stored in labeled cyrovials at minus 25-70⁰ C before shipment to the appropriate laboratory for
analysis. After full recovery from anesthesia, all raccoons and skunks were released at their site
of capture.
Target species swab sampling
The same animal capture and handling procedures were followed from day 1-6 post-ORV with
ONRAB® to collect oral swab samples (Appendix B). However, live trapping was confined to
the intercellular spaces between the four primary sampling cells 1-2, 2-3, and 3-4. This sampling
scheme was used to reduce the chance of trap shyness among raccoons and skunks post-ORV
with ONRAB® to collect blood sera and other samples, which began the recommended 5-weeks
after bait distribution (C. Fehlner-Gardiner, personal communication) and would include
recaptures from the pre-ORV sampling period. Swab samples were labeled and stored in
universal viral transport tubes (Becton Dickinson, #220222) containing 3 ml of transport medium
and shipped in near real time to the Animal Health Diagnostic Center, Cornell University for
analysis.
Target and nontarget species histopathology sampling
Victor Rat (model BM205) and mouse (model BM154) traps were used to capture small
mammals for tissue sampling from major organs. Trapping began on July 21, 2011, two weeks
prior to serological baselines samples, and continued opportunistically up to the distribution of
ONRAB® baits September 16, 2011. These samples were supplemented with live trapped
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nontarget captures to assure a diverse representation of faunal samples for histopathological
investigation. Larger mammals and birds were donated from WV, Division of Natural Resources
or collected by live trapping or shooting.
Histopathological samples were also collected from target and nontarget species within the
ONRAB® ORV zone after the 6-day swab sampling period. No target species were collected for
histopathology from the four primary sampling cells within the field trial zone (Figure 2).
Necropsies were performed on animals on the day of capture and tissues were harvested, placed
in labeled vials in 10 percent buffered formalin, stored for a short period, and shipped for
laboratory analysis to MD Anderson Cancer Center (Houston, Texas) according to the protocol
in Appendix B.
RVNA Antibody Determination
Serum was shipped frozen in labeled, cryovials within containers of dry ice to the CDC Rabies
Program Laboratory upon completion of the Pre-ONRAB® sampling period and again after the
Post-ONRAB® sampling period. The RVNA were determined at CDC using the Rapid
Fluorescent Focus Inhibition Test (Centers for Disease Control and Prevention, 2011). Samples
with I.U.≥0.06 were deemed indicative of positive RVNA activity.
Human Adenovirus (Serotype-5) Antibody Determination
Serum was also shipped frozen in labeled, cryovials within containers of dry ice to the Animal
Health Diagnostic Center, Cornell University to determine antibody levels of HAd5 upon
completion of the Pre-ONRAB® sampling period and again after the Post-ONRAB® sampling
period. The adenovirus virus neutralization (VN) assay for Ad-5 followed standard procedures
for VN assays in microtiter plates. Two-fold serum dilutions (50 ul) in duplicate were mixed
with 100-300 TCID50 of Ad-5 (VR-5 ATCC) in a 50 ul volume. Mixtures were allowed to
incubate for at least 1 hr at room temperature. A 100 ul volume of indicator cells (A549 ATCC) was added to each well and the plates were placed in a CO2 incubator at 37⁰C for 6 days.
Wells were scored for the presence or absence of typical Ad-5 cytopathology. Positive serum
controls were an equine anti Ad-5 (CDC) and a bovine anti Ad-5 (ARS-USDA).
Tetracycline Biomarker
First premolars extracted from each live captured and anesthetized raccoon or skunk were
shipped in small, labeled Manila envelopes to Matson’s Laboratory (Missoula, MT) for
tetracycline and specific age determination based on cementum annuli counts. For the analysis in
this report only juvenile and adult age classes could be evaluated until age specific age results
become available.
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ONRAB® Detection from Oral Swab Samples
Oral swab samples were shipped in universal viral transport tubes (Becton Dickinson, #220222)
containing 3 ml of transport medium to the Animal Health Diagnostic Center, Cornell University
for analysis. Complete descriptions of the swab sampling protocol and the quantitative real time
polymerase chain reaction analysis (qPCR) can be found in Appendices B and C, respectively.
Histopathology
Field studies
These studies are being conducted under contract with MD Anderson Cancer Center, Houston,
Texas. A complete description the protocol is present in Appendix B.
Captive studies
The study protocol for captive histopathology studies conducted at the WS, NWRC animal
research facilities in Ft. Collins, Colorado is provided in Appendix D. The species evaluated
included: Eastern Woodrat (Neotoma floridana), Cottontail Rabbit (Sylvilagus floridanus),
Opossum (Didelphis virginiana), Fox Squirrel (Sciurus niger) and Eastern Wild Turkey
(Meleagris gallopavo silvestri). Because animals in the wild could consume more than one bait,
this study evaluated animals exposed to a 10x dose of ONRAB® and controls.
ONRAB® Bait Contact
Enhanced surveillance for human and domestic animal bait and vaccine contact was a critical
component of the ONRAB® field trial to measure and address potential human and pet safety
issues. Typically during ORV projects, reports of human or pet contact with ORV baits occurs
when a person who has found a bait calls the toll-free number printed on the bait, or when a
person directly contacts federal, state or local agencies after a bait is found (Roess 2012). Each
ONRAB® bait distributed as part of this field trial contained a warning label (“Rabies vaccine,
DO NOT TOUCH. Live adenovirus vector”) (Figure3) and was marked with a toll-free number
that put callers in direct contact with public health officials at the West Virginia Department of
Health and Human Services (WVDOH). To assist the WVDOH in documenting and managing
human bait contacts, CDC and WS developed a recommended SOP for ONRAB® bait contacts
through a detailed algorithm (Figure 5).
To improve surveillance for bait and vaccine contacts, a communication campaign was
cooperatively implemented by WS specifically for the ONRAB® field trial. This campaign
focused on raising public awareness of the field trial, enhancing public understanding of ORV
and the associated risk of contact with baits and vaccine, and to increase reporting of potential
vaccine exposures.
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At the foundation of these communication efforts was the preparation and publication of a WS
environmental assessment (EA) in cooperation with the USDA Forest Service (USFS) entitled
"Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in West
Virginia." The EA analyzed the potential environmental effects of a proposed field trial in West
Virginia, including portions of USFS lands but excluding Wilderness areas, to determine the
safety and immunogenicity of the HAd5-rabies glycoprotein recombinant vaccine in raccoons
and striped skunks. A 30-day public comment period (August 8th through September 7th, 2012)
resulted in a total of 13 comments received from private citizens and representatives from public
health, agriculture, and natural resources agencies in the U.S. and Canada. The majority of
comments were supportive. Three comments were addressed, including one comment that
expressed concern about the potential for human exposures and methods for managing these
events, and another comment that focused on concerns that WS had not properly informed the
residents of WV about the pending field trial. The final comment was related to a National Park
Service request for language changes in the EA.
WS also enhanced communication efforts through preparation and distribution of a national press
release about the field trial. The press release was picked up by the Associated Press and widely
distributed. In addition, at least four T.V. and newspaper interviews were conducted at a media
event and at a Greenbrier County, WV Commission meeting, where a detailed presentation on
the ONRAB® field trial was given to County Commissioners and the public. Finally, WS in
collaboration with WVDOH, Ontario Ministry of Natural Resources, West Virginia Department
of Agriculture, West Virginia University, West Virginia Division of Natural Resources and the
USFS developed a list of talking points to assist in the coordination of key field trial messages
provided to the public, facilitate data collection on potential bait and vaccine exposures, and
ensure safety concerns were adequately addressed by all cooperating agencies.
Statistical Methods
Descriptive statistics were used to characterize the proportion of raccoons that seroconverted
between pre- and post-baiting trapping operations. We used contingency tables and the CochranMantel-Haenszel (CMH) (Agresti, 1996) test to determine whether the proportions of individuals
sampled in pre- and post-ORV capture efforts differed among sampling cells (1-4). The CMH
tests were used to determine if age, sex and seroconversion status were conditionally
independent across sampling cells. Separate CMH analyses were conducted on pre- and postORV data sets. We used the McNemar test for dependent samples to determine whether the
proportion of seroconverted individuals captured differed between the pre- and post-baiting
sampling sessions. Finally, we conducted a factorial ANOVA to determine if recapture distance
differed between sampling sites, and age and sex classes.
We used Cochran-Mantel-Haenszel tests to determine whether relationships existed between biomarking, serology, age and sex. Among post-ORV samples, we explored detected differences by
multiple logistic regression. Significance was set at P<0.05.
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All statistical analyses were conducted in SAS 9.1 (SAS Institute, 2002)
RESULTS AND DISCUSSION
Target Species Serology
Raccoons sampled during the pre-baiting trapping period displayed a 9.6 percent sero-prevalence
for RVNA. Geographic cell-to-cell proportion of seroconverted raccoons trapped during preORV sampling did not differ relative to sex (CMH = 2.53, df = 1, p = 0.11) or age (CMH = 2.81,
df = 1, p = 0.094) classes. The sampled cell-to-cell (Figure 4) proportion of sero-positive
demographic classes ranged from 0-6%, and adults comprised a greater proportion of sampled
individuals than did juveniles (Table 4).
By contrast, 49.4 percent of raccoons sampled during the post-ORV trapping period had
detectable RVNA. The sampled cell-to-cell proportion of sero-positive demographic classes
ranged from 0-37% (Table 4) differed both by sex (CMH = 3.98, df = 1, p = 0.046) and age
(CMH = 6.46, df = 1, p = 0.011) classes. These differences can be attributed to a lower
proportion of sero-positive females in cell 1 (χ2 = 6.81, df = 1, p = 0.009), and a lower proportion
of sero-positive juveniles in cell 4 (χ2 = 5.82, df = 1, p = 0.016). The difference in the
proportions of individuals that were categorized as sero-positive was significantly higher
(S=102.25, df = 1, p < 0.001) in the post-ORV with ONRAB® (49.4%) sampling period than in
the pre- ONRAB® (9.6%) period.
The distance between pre and post- ONRAB® recaptures differed by cell (F = 6.78, p = 0.002)
and not by sex (F = 0.51 p = 0.48) or age class (F = 1.77, p = 0.19). The mean distance between
recaptures was greatest for cell 2 (553 m), followed by cell 3 (260 m), cell 4 (212 m), and cell 1
(101 m).
Sero-positivity of 9.6 percent among raccoons (n=395) sampled prior to ONRAB® baiting
(Table 5) in the ORV naïve raccoon rabies enzootic field trial area was higher than has been
recorded for areas of similar status (mean=4.9%, SD=4.8, n=13) (Tables 6 and 7). Possible
reasons for the higher baseline include naturally acquired immunity from sub-lethal exposures to
raccoon rabies virus or movements of orally vaccinated raccoons into sampling cells from the
adjacent Raboral V-RG® zone. However, only 3 of 31 sero-positive raccoons were also
biomarker-positive (Table 8). In addition, the coated sachet is the primary bait type distributed in
the adjacent Raboral V-RG®, which does not contain biomarker. Twenty-five of 310 seronegative raccoons were biomarker-positive from the pre-ORV sampling period (Table 8),
suggesting that the environment may be a source of tetracycline exposure. Raccoon rabies in this
general area during the five years prior to the field trial (Figure 6) suggest the higher seropositivity in the pre-ORV sample is more likely related to naturally acquired immunity. Previous
studies have reported higher levels of RVNA in raccoon populations in areas naïve to the
raccoon rabies virus variant where there have been no vaccination efforts (McLean, 1971;
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Ramey et al., 2008). Lastly, there are no known wildlife rehabilitation facilities in the immediate
area that may have released sufficient numbers of hand-inoculated raccoons by off-label use of
commercial rabies vaccines to affect pre-ORV levels. Such activities are not legal in West
Virginia.
The 49.4 percent post-ORV with ONRAB® (uncorrected for the 9.6%) sero-positivity represents
the highest population RVNA level WS has observed after a first baiting of a naïve area at 75
baits/km2 where antibody baselines had been measured prior to ORV. Nine percent (3/32) were
tetracycline and sero-positive in the pre-ONRAB® sample (Table 8), compared to 40 percent
(48/123) post-ORV with ONRAB® (Table 9). Among pre-ORV samples, no relationships were
detected between bio-marking, serology, age, or sex (P=0.6336). However, among post-ORV
samples, differences were noted relative to age (P=0.0007) predicted sero-positivity, with adults
having >3 times higher odds of being sero-positive than juveniles (OR=3.133). Once specific age
class data become available, biomarking will be evaluated further as younger raccoons have been
reported to biomark with tetracycline more easily (PM1 and canine teeth only) than older
animals (Algeo et al., in revision) due to active tooth growth (Linhart and Kennelly, 1967), Most
important is that tetracycline biomarking was related to serological response (P=0.0001).
That biomarker-positives were less than RVNA-positives can be attributed in part to the use of
the first premolar, a tissue known to be inferior to canines or mandibular bone to evaluate
tetracycline deposition (Linhart and Kenelly, 1967; Algeo et al., in revision). The premolar was
selected because it was more important to release raccoons and skunks to increase the probability
of recaptures in the post-ORV sample than to euthanize animals to extract canine teeth for
evaluation. In spite of this, only 27 raccoons caught during post-ORV trapping were recaptured
from the pre-ORV period. One of 27 raccoons was RVNA-positive during pre-ORV and 8 of 27
had evidence of RVNA post-ORV. The single individual that had antibodies pre-ORV
(I.U.=0.06) was also positive post-ORV with an apparent anamnestic response (I.U.=0.32). No
skunks were recaptured in the post-ORV period.
While this field trial was not specifically designed to compare ONRAB® and Raboral V-RG®, a
sero-positivity of 17.0 percent (n=11, SD 9.9%, uncorrected for RVNA of 4.9%, (n=13, SD
4.8%) was observed after a first baiting with Raboral V-RG® in naïve areas under essentially the
same initial ORV baiting characteristics during 2001 to 2009 in Alabama, Florida, Georgia,
Maine, North Carolina Pennsylvania, Tennessee and Virginia and similar raccoon density indices
(U.S. Department of Agriculture, 2011c) as in this field trial except in Florida (Tables 6 and 7).
These results are in line with those reported by Fehlner-Gardiner et al. (2012) who found
essentially a two-fold higher sero-positivity at 73 percent for ONRAB® in New Brunswick,
compared to 29 percent for Raboral V-RG® across the border in Maine.
Although comparative seroconversion samples were not collected in the adjacent Raboral VRG® zone in West Virginia post-ORV during 2011, in the four years previous to the ONRAB®
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field trial, RVNA population levels ranged from 18.5 percent (n=135; 2008) to 46.4 percent
(n=84; 2007, Table 10). These percentages represent RVNA levels for areas that have been
subject to annual ORV campaigns at 75 baits/km2 since 2001.
The Raboral V-RG® zone in Virginia is the closest area for reference, at 166 km linear distance
southwest from the ONRAB® field trial zone (Figure 7). During 2011, a 57.1 percent (n=177)
sero-positivity was recorded in this area, which contains similar habitats but has been baited at
75 baits/km2since 2002. This represents a rare high RVNA, which may be partially explained by
the presence of raccoon rabies virus variant in the area (Figure 7). While the same effect may
apply to the field trial area (figure 6), biomarker in the ULTALITE® bait provides context for a
vaccine-induced RVNA response. Unfortunately, the coated sachet used to deliver Raboral VRG® does not contain biomarker, which would have aided in this evaluation. Considerable
variation in RVNA has been observed 2007 to 2010 in the general vicinity of the Virginia
reference area, with levels ranging from18.4 (n=114; 2010) to 39.0 percent (n=210; 2007) (Table
10). As an index, 11 percent (5/45) of ORV events examined during a 3-year period (2006 to
2008) at 75 baits/km2 from 12 eastern states exceeded the sero-positive rate observed in this
field trial. The mean sero-positivity was 32.3±12.8 (SD) percent for these 45 ORV events.
RVNA for all of these ORV events was in relation to areas that had been baited at least twice;
most had been baited for several successive years. However, given this rare high level of 57.1
percent, we plan to evaluate the same ORV area in Virginia in 2012, with a similar sampling cell
format as used in West Virginia. In addition, formal sampling cells are being planned for preand post-ORV within the Raboral V-RG® and the ONRAB® zone in West Virginia in 2012. This
design improvement will facilitate determining if population immunity will increase significantly
in response to a second successive year of ONRAB® baiting at 75 baits/km2 and allow for a more
formal comparison with Raboral V-RG®.
An inadequate sample of skunks was captured to establish a population baseline for RVNA and
evaluate the response to ONRAB®. Only one of 20 skunks had detectable RVNA in the PreORV sample; one of 27 had RVNA post-ORV with ONRAB® (Table 5). All other species in
Table 5 are reflective of incidental captures of rabies reservoir species in North America
(Blanton et al., 2011).
There was no evidence of HAd5 antibodies in 416 animals sampled during the pre-ORV period
(Appendix E). Seven of 296 (2.4%) samples evaluated post-ORV demonstrated HAd5 VNA; 6
raccoons and 1 skunk (Appendix F). Low seroconversion may be expected for a human adapted
virus. Monitoring for anamnestic responses will be incorporated into the evaluation of baiting
with ONRAB® in after a second baiting as projected for September 2012.
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Histopathology
Field study
Diverse fauna were sampled for histopathological analysis in the pre and post-ONRAB® periods.
Small rodents such as Peromycus sp. and Microtus sp. constituted the largest group sampled that
included other rodents, lagomorphs, cervids and birds (Table 11). The results are not available at
this time, but will be provided as an addendum to this report after they are received from MD
Anderson Cancer Center (Houston, Texas, USA). Our expectation is that these results will be
available by the end of April.
Captive study
The species selected for captive studies represent common fauna to southeastern West Virginia
and will serve to complement the spectrum of species that have already been evaluated for
histopathologic effects relating to ONRAB® exposure in Canada (Knowles et al., 2009). Similar
histopathologic results in vaccinates and control animals were observed for the four species in
which the analysis is completed, suggesting no untoward effects from ONRAB® consumption at
a 10x dose above exposure to single bait. The woodrat analysis is nearing completion. The
results from this captive study in tandem with previous results from Canada (Fehlner-Gardiner et
al., 2012) serve as the reference for histopathology from wildlife in southeastern West Virginia.
The summary report from the captive histopathology study submitted by WS, NWRC is in
Appendix G.
ONRAB® Detection from Oral Swab Sampling Day 1 – 6 Post-ORV
Swab samples were collected from 125 target and nontarget individuals live-trapped from day 16 post ORV baiting to determine ONRAB® presence in the oral cavity. Individual raccoons
captured on days 2, 3 and 4 and an opossum on day 4 had qPCR values <35, which are
considered strong positives (Knowles et al. 2009) (figure 8). An additional nine raccoons and
four opossums with >35 qPCR values <40 were captured on days 1-4. No ONRAB® was
detected on days 5-6. Two of 15 raccoons and two of 12 opossums had >35 qPCR values <40 on
day 1. While these are not considered strong positives, they represent the only animals sampled
that could have had vaccine contact during the first night after ONRAB® distribution. It is not
possible to determine the specific day in which vaccine contact may have occurred for remainder
of the animals deemed positive from day 2-4.
ONRAB® Bait Contacts
No human or domestic animal bait or vaccine contacts were reported to the WVDOH or WS
associated with the ONRAB® field trial in 2011, despite notification of the field trial and media
events that included bait descriptions and the integration of enhanced to document potential bait
exposures and reduce potential safety issues.
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Enhanced surveillance and tracking of bait and vaccine contacts are an integral component of
ORV projects conducted by WS in the U.S. (Roess et al. 2012). About 120 million Raboral VRG® baits have been distributed since the WS ORV program inception in 1995, yet only 1,464
people reported contacting or potentially contacting a bait (i.e., picking up bait, finding a bait in
yard, or removing bait or sachet from pet’s mouth, feces, or vomit - any type of contact with a
bait is also defined throughout the document as an “exposure”). This equates to one human
exposure per 68,521 baits distributed, or 0.0015% contact cases (U.S. Department of Agriculture,
2011b). In addition, exposure cases were generally insignificant, as most involved finding an
intact bait. Very few cases involved touching a broken bait, sachet, or liquid vaccine.
Furthermore, of the 0.0015% of contact cases reported since 1995, only two known adverse
reactions have been reported (USDA 2010a; CDC 2009).
From 1995 - 2008, U.S. Department of Agriculture (2011b) documented only 1,327 instances
where a pet or other domestic animal had contact with a bait. This equates to 1 domestic
exposure per 75,596 baits disbursed or 0.001 % contact cases. In addition, U.S. Department of
Agriculture (2011b) documented that 261 incidents were reported in which pets came into
contact with a bait in 2008. However, there were no reports of pets or other domestic animals
experiencing any type of adverse reaction, other than 8 dogs who experienced vomiting or
diarrhea after ingesting a number of baits. The dogs involved in these adverse reactions have
reportedly not experienced any substantive or long term adverse effects. Domestic animals that
bite into and ingest a bait of either Raboral V-RG® or ONRAB® are most likely to be immunized
against rabies virus or receive a boost from a previous vaccination.
As in the U.S., ONRAB® baits distributed in Canada are marked with a toll-free number that the
public can call if they see or have contact with bait or vaccine. Between 2006 and 2011 over 3.9
million ONRAB® baits were distributed in Ontario. There were a total of 64 calls received in
which a person reported finding or contacting a bait during this period. This equates to
approximately 1 call for every 65,140 baits distributed or 15 calls for every 1 million baits
distributed, essentially the same as the call rate for Raboral V-RG®. The total number of calls
received involving possible contact (i.e. vaccine contact not officially confirmed) with vaccine as
a result of handling a punctured bait or removing a bait from a dog’s mouth or dog chewing a
bait was 15. The rate of possible contact with vaccine equates to 1 contact for every 260,560
baits distributed. There were no reports of adverse events associated with humans from any of
the reported contacts (Ontario Ministry of Natural Resources 2007, 2008, 2009, 2010, 2011).
The province of Quebec has also been distributing ONRAB® vaccine baits since 2007. Between
2007 and 2009, despite the distribution of almost 2 million baits, there were only 16 reports of
human exposures (Mainguy and Canac-Marquis unpublished). In 2010, just over 1 million
ONRAB® baits were distributed with no human bait contacts reported (Ontario Ministry of
Natural Resources, 2011)
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The relatively low numbers of bait and vaccine contacts associated with ONRAB® in Canada and
no reported bait or vaccine exposures documented during this field trial in the U.S. could be
related to several factors. The ONRAB® ULTRALITE bait differs from Raboral V-RG® baits
(coated sachets and fishmeal polymer baits) in color and attractants. The ONRAB® bait matrix is
a khaki green color, which may aid in camouflaging in most habitats. Also, the ONRAB® baits
contain a sweet scent and flavor rather than scent associated with fishmeal for Raboral V-RG®,
which may decrease the likelihood of baits being found by cats and dogs. Maintaining a system
for enhanced surveillance for human and domestic animal bait contact will be important as field
trials expand to other areas that include more urban and suburban habitats with increased human
and pet populations that often require higher baits densities to meet management objectives.
RECOMMENDATIONS
The following recommendations are the result of the encouraging outcome of this initial
ONRAB® field trial.
1) The West Virginia trial should be replicated and include at least two similar sized,
buffered sampling cells in the adjacent Raboral V-RG® ORV zone for comparative
purposes. Pre and Post-ORV raccoon and skunk samples should be collected at sufficient
sample size for RVNA serological analysis to address the question: does a successive
second year of ONRAB® vaccination significantly increase raccoon population immunity
above year one? These data will be required as a basis for year three ORV to determine
if the population immune response becomes asymptotic at year two similar to the pattern
generally observed for Raboral V-RG®, but at a significantly higher level. Leveling off
of the population immune response should in turn be analyzed in the context of raccoon
age structure, which is likely a correlate as a reflection of population dynamics.
2) Field trails should be expanded in 2012 to areas with an elevated risk of raccoon rabies
spreading to naïve areas. The Ohio Contingency Action zone (east of Cleveland, Ohio) ,
which is interspersed with urban and suburban development, represents the highest
priority site and is ideally suited for an evaluation of safety with respect to bait contacts
and immunogenicity associated with hand baiting at 150 baits/km2. This proposed
expansion would introduce new complexities associated with unique bait distribution
patterns that should be evaluated for broader use of ONRAB®. As a results of trapvaccinate-release efforts in the Ohio Contingency Action zone, a history of raccoon
populations and RVNA exists. The challenge will be to focus sampling effort on the
naïve juvenile class as well as the overall population immunity for evaluating the postORV with ONRAB® treatment. In addition, measuring bait contacts under higher bait
and human densities represents a key area of interest.
3) In 2006, raccoon rabies was first confirmed in Quebec, with Vermont as the likely source
of the emergence of this rabies virus variant. Since 2006, Quebec has made extensive
commitments to raccoon rabies control and surveillance (Rees et al., 2011). No cases of
raccoon rabies have been detected in the Province since May 2009, with the use of
ONRAB® central to their strategy for elimination. Quebec has expressed an interest in
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creating a greater distance buffer to enhance protection against the emergence of raccoon
rabies in Montreal. Therefore, a field trial in northern Vermont and New Hampshire and
Northeastern New York should be elevated in priority to prepare for collaboration with
Quebec and the likelihood of a commitment of Quebec resources to this effort in 2013. In
the U.S., this area is largely rural, not unlike West Virginia, but the field trial would
occur in an area that has been subject to ORV and trap-vaccinate-release (TVR). This
field trail should be structured to allow for a comparison of naive areas in Vermont to
similar areas in West Virginia, as well as first ONRAB® baiting in previously vaccinated
(Vermont) and (unvaccinated) areas (West Virginia).
4) The Niagara Frontier, connecting New York and Ontario, represents another high risk
corridor for raccoon rabies movement and therefore is a priority for a future field trial in
2012, or more likely 2013, depending on available resources and other factors. TVR had
been used for several years between the Welland Canal and the Niagara River in Ontario
to provide an immune barrier against spread and establishment of raccoon rabies from
New York. In New York, ORV with Raboral V-RG® has been in place on the Niagara
Frontier since 1996 (U.S. Department of Agriculture, 2007), with rabies perpetuating in
raccoons and skunks in Erie and Niagara Counties, New York, which border Canada.
The Niagara Frontier includes the City of Buffalo and Niagara Falls, and as such has
some similarities with the proposed field trial area east of Cleveland, Ohio.
5) In 2013, the St. Lawrence River Valley, New York and northeastern Tennessee represent
high risk areas that should be considered as field trial sites, if additional field data are
required to support the licensing of ONRAB®.
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TABLES
Table 1. List of county, state, federal and international entities from governments and non-government
organizations that collaborated and participated in the West Virginia ONRAB® field trial, 2011.
Agency/Organization Name
United States Department of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services, National
Wildlife Research Center (USDA, APHIS, WS, NWRC)
USDA, APHIS, Center for Veterinary Biologics (CVB)
USDA, APHIS, Legislative and Public Affairs (LPA)
USDA, APHIS, Policy and Program Development (PPD)
Centers for Disease Control and Prevention (CDC)
United States Forest Service (USFS)
West Virginia Department of Agriculture
West Virginia Department of Health and Human Resources
West Virginia Division of Natural Resources
Greenbrier, Monroe and Summers County Commissioners
Animal Health Diagnostic Center, Cornell University College of Veterinary Medicine
Ontario Ministry of Natural Resources
Quebec Ministère des Ressources naturelles et de la Faune
Canadian Food Inspection Agency
Trent University
Artemis Technologies, Inc.
Dynamic Aviation Group, Inc.

Table 2. Candidate oral rabies vaccines considered for field testing in the U.S. over the past five years.
Vaccine
Recombinant?
Licensed in U.S.?
Licensed outside U.S.?
Interest in U.S.?
Proprietor1

ONRAB

®

yes
no
pending
yes
Artemis

SAG2

CAV2

SPN SASGAS

no, modified-live
no
yes
yes
Virbac

yes
no
no
yes
MTTI

yes, reverse genetics
no
no
yes
IDT

1

Artemis Technologies, Inc. (Ontario, Canada); Virbac (Carros, France); Molecular Targeting Technologies, Inc. (Pennsylvania, USA); IDT
Biologika (Dessau, Germany).
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Table 3. Pre- (baseline) and post-ONRAB® oral rabies vaccine sampling emphasis.
Activity

Pre-ONRAB

Enhanced rabies surveillance
Rabies virus serology
Human adenovirus serology
Biomarker
Histopathology (target and non-target species)
Oral cavity swab samples
Monitoring for abnormalities among animals
®

ONRAB bait contacts

®

Post-ONRAB

yes
yes
yes
yes
yes
no
yes

yes
yes
yes
yes
yes
yes
yes

n/a

yes

®

Table 4. Percent of sero-converted raccoons and corresponding sample size for pre- and post-ONRAB® baiting.

Interval
Pre-bait

Post-bait

Cell
1
2
3
4
1
2
3
4

Adult Male
%
n
3.9
32
4.1
41
4.4
49
5.9
24
21.6
27
14.6
14
37.3
28
25.0
39

Adult Female
%
n
1.9
31
4.1
27
3.6
33
1.1
25
8.4
27
17.1
8
25.4
25
16.2
30

Juvenile Male
%
n
0.0
21
2.0
18
0.8
12
0.0
12
7.2
16
9.7
11
5.1
4
1.2
7

Juvenile Female
%
n
0.0
17
0.0
10
0.8
15
3.6
20
4.8
13
7.3
8
1.7
2
0.0
4

Table 5. Percent of sero-converted animals sampled for pre- and post-ONRAB® field trial in West Virginia, 2011.
Pre-ONRAB®
Species
Raccoons
Striped skunks
Gray foxes
Red foxes
Coyotes
Total

%
9.6
5.0
0.0

9.4

n
395
20
1
0
0
416

Post-ONRAB®
%
49.4
3.7
100
66.7
100
45.9

n
263
27
2
3
1
296
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Table 6. Percent of sero-converted raccoons where Raboral V-RG® oral rabies vaccine was distributed for the first
time following baseline sample collection in an ORV naive area and indexes to raccoon population density in
eastern states (2001-2009).1
Mean
Raccoon
Density

n
Studies

6.5

2

8.9

2

State

Year

Bait Density (per
km2)

Alabama

2002

naive

2.9

68

2003

75

32.8

67

Region2
Georgia-Alabama-Tennessee
(GAT)
Georgia-Alabama-Tennessee
(GAT)

2002

naive

11.3

##

Selma

2004

75

13.1

99

Selma

2005

naive

1.2

84

Birmingham

2005
2003

75
naive

2.7
9.1

##
99

Birmingham
Mainland (not Pinellas County)

n/a

0

2003

75

9.2

65

17

5

Georgia

2003

naive

0

19

2004
2002

75
naive

30.2
14.3

##
21

n/a

0

Maine

Mainland (not Pinellas County)
Georgia-Alabama-Tennessee
(GAT)
Georgia-Alabama-Tennessee
(GAT)
Hodgdon

2003

naive

0

11

Hodgdon

2003

70

19.5

82

Hodgdon

3.6

2

2007

naive

1.4

74

Caribou
12.1

2

Florida

%

n

2009

75

26.4

##

Caribou

North
Carolina

2005

naive

3.3

30

Appalachian Ridge

75
naive

7.5
9.9

##
##

Appalachian Ridge
Appalachian Ridge

n/a

0

Pennsylvania

2005
2002

75
naive

12.8
3.3

39
30

Appalachian Ridge
Appalachian Ridge

n/a

0

Tennessee

2002
2002
2002
2001

75
naive

10.8
9.1

74
33

Appalachian Ridge
Appalachian Ridge

9

1

Virginia

2002

naive

3.4

29

Appalachian Ridge

2002

75

22.1

68

Appalachian Ridge

4.7

2

Total

naive

mean=4.9±4.8

n=13

Total

70/75

mean=17.0±9.9

n=11

1

Information subject to minor change based on revised data entry to Wildlife Services' Management Information System; accessed March 2012.

2

Regions represent distinct ORV zones within a given state where sampling was conducted independent of other regions.

3 Means and standard deviations of naive vs. baited areas were generated from 13 and 11 events, respectively (n=13, n=11).
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Table 7. Raccoon density indexes within or near ONRAB® field trial area in West Virginia, 2006-2010.
Density (raccoons/km2)

Year

Study Name

County

2006
2007
2010
2010
2010
2010

WVGREENB06
WVGREENB07
WV00310
WV00410
WV00510
WV00610

Greenbrier
Greenbrier
Greenbrier
Greenbrier
Monroe
Monroe

8.2
12.2
12.0
10.7
6.6
7.0

Area Habitat Class
Rural (mixed forest)
Rural (mixed forest)
Agriculture (pasture/hay)
Rural (mixed forest)
Rural (mixed forest)
Rural (mixed forest)

Table 8. Seroconversion and biomarker results for 341 raccoons sampled prior to ONRAB® ORV distribution in
West Virginia, 2011.
Biomarker Negative
male
female

Pre-ORV
Sero-negative
Sero-positive

adult
juvenile
adult
juvenile

117
38
15
3

Biomarker Positive
male
female

87
43
9
1

5
11
1
1

6
3
1
0

Table 9. Seroconversion and biomarker results for 250 raccoons sampled after ONRAB® ORV distribution in West
Virginia, 2011.
Post-ORV
Sero-negative
Sero-positive

adult
juvenile
adult
juvenile

Biomarker Negative
male
female
33
41
19
13
41
28
2
4

Biomarker Positive
male
female
7
5
4
5
19
13
12
4

Table 10. Percent of sero-converted raccoons sampled post-ORV (Raboral V-RG® in West Virginia and Virginia,
2007-2011.

Year
2007
2008
2009
2010
2011

West Virginia
%
n
46.4
84
18.5
135
24.0
179
20.5
239
no sampling conducted

Virginia
%
39.0
32.0
18.8
18.4
57.1

n
210
147
319
114
177
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Table 11. Number of histopathology samples collected pre- and post-ORV during the ONRAB® field trial in West
Virginia, 2011.
Species
Bear (Ursus americanus)
Coyote (Canis latrans)
Crow (Corvus brachyrhynchos)
Deer (Odocoileus virginianus)
Fox (Urocyon cinereoargenteus and Vulpes vulpes)
Opossum (Didelphis virginiana)
Rabbit (Sylvilagus floridanus)
Raccoon (Procyon lotor)
Rodents, small (Peromyscus and Microtus spp.)
Skunk (Mephitis mephitis)
Squirrel (Sciurus carolinensis and Sciurus niger)
Vulture (Cathartes aura)
Woodchuck (Marmotamonax)
Total

Pre-ONRAB®

Post-ONRAB®

4
3
9
4
3
9
8
9
201
7
13
10
10
290

1
3
9
2
3
10
9
10
221
4
10
8
10
300
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Figure 1. Raboral V-RG® oral rabies vaccine distribution targeting raccoons, gray foxes and coyotes in the United
States, 1992-2011.
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Figure 2. Oral rabies vaccine distribution zones targeting raccoons, gray foxes and coyotes in the United States,
2011. Inset includes ONRAB® ORV zone relative to Raboral V-RG® zone and ONRAB® sampling cell details.
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Figure 3. ONRAB® baits utilized in oral rabies vaccine field trial in West Virginia, 2011. (Photo:
http://www.mnr.gov.on.ca/en/Business/Rabies/2ColumnSubPage/STEL02_166285.html accessed March 2012.)
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Figure 4. Preselected random trapping points and subsequent raccoons and skunks captured during pre- and postONRAB® trapping periods in West Virginia, 2011.
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SUGGESTED SOP FOR ONRAB ORAL RABIES VACCINATION BAIT CONTACTS (HUMAN)

*Please note this is a suggested SOP. State and county HDs are not required to follow this SOP and may alter the components to accommodate their program.*

WAS ONRAB
BAIT INTACT?

NO

WAS THERE DIRECT
EXPOSURE TO SACHET
CONTENTS (vaccine)?
If >1 contact, complete
SOP for each contact.

YES
IMMUNOCOMPROMISED?
1. CONTACT PERSONAL PHYSICIAN (with patient permission)

PREGNANT?
MUCOSAL OR EYE EXPOSURE?

NO

YES

WAS THERE INDIRECT
EXPOSURE TO SACHET
CONTENTS (vaccine) THROUGH
CONTACT WITH EXPOSED
PERSON OR ANIMAL?

VACCINE HAD CONTACT WITH
OPEN OR BREACHED SKIN?

YES

2. CONTACT APPROPRIATE STATE AND COUNTY PERSONNEL
3. CONTACT CDC1 FOR CONSULTATION

WEEKLY FOLLOWUP CALLS FOR 3
WEEKS (at least once 10-14 days
post exposure).
YES

NO

PATIENT IS ENCOURAGED TO CALL
IF THERE IS ANY ILLNESS.

NO

END FOLLOWUP
AFTER 3RD WEEK.

ANY ILLNESS?
NO

LOW RISK.
LOW RISK.

FOLLOWUP AS NEEDED.

FOLLOWUP AS
NEEDED.

YES

1. CONTACT PATIENT’S PERSONAL PHYSICIAN (with patient permission)
2. CONTACT APPROPRIATE STATE AND COUNTY PERSONNEL
3. CONTACT CDC1 FOR CONSULTATION INCLUDING DIAGNOSIS AND TREATMENT
4. STATE HD, CDC, AND TREATING PHYSICIAN CONFERENCE CALL TO DISCUSS CASE
MANAGEMENT

LOG CALL. FILL OUT FORM FOR ALL CALLS INVOLVING CONTACTS – INDIRECT AND DIRECT CONTACT, INTACT AND OPEN BAITS.
1 CDC Emergency

Operations Center: 770-488-7100
*This document was originally created for V-RG ORV by Andrea McCollum and Brett Petersen (ige3@cdc.gov),
2010 and modified by Richard Chipman (richard.b.chipman@aphis.usda.gov) for ONRAB in 2011.
The content is based on information and SOPs from USDA, TX, and OH.

Figure 5. Suggested standard operating procedure (SOP) for documenting and managing human contacts with
ONRAB® baits during field trial in West Virginia, 2011.
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Figure 6. Raccoon rabies variant case history in West Virginia 2007-2011 within an 83 km radius of the center of
the 2011 ONRAB® ORV zone.
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Figure 7. Raccoons sampled for rabies virus neutralizing antibodies (RVNA) post-ORV Raboral V-RG®
distribution and cases of raccoon rabies virus variant within an 83 km radius of the center of the sampled raccoons,
Virginia, 2011.
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Figure 8. Total unique captures for oral swab sampling and PCR positives by species, day 1-6 post-ORV with
ONARB® distribution September 16, 2011 (others included gray squirrel and cottontail rabbit).
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APPENDICES
Appendix A: Final Outline for Proposed ONRAB® Oral Rabies Vaccine Field Trial in West
Virginia
1) Site location (Figure 1)





State: Southeastern West Virginia
Counties: portions of Greenbrier, Monroe, Summers
Towns: Alderson, Fairlea, Falling Springs, Lewisburg, Ronceverte
Field trial plot coordinates: 38.044, -80.421; 37.920, -80.241; 37.566, -80.932; 37.445,
-80.753.

2) Rationale for field trial site selection









Near the strategic center of the Appalachian Ridge ORV zone created with Raboral VRG®
Raccoons and skunks present
Raccoon rabies perpetuates east of existing ORV zone
Proposed zone in a single state
Local support within state and county
Low human population
WS infrastructure in place
Site allowed for a broader seasonal window for baiting than potential sites farther north

3) Field trial plot size



Total area: 1,478.11 km2 [1,450.28 km2 (fixed wing baiting) and 27.83 km2 (ground
baiting)]
4 distance buffered cells: 11.2 x 11.2 km post-ORV sampling cells: 126.84 km2

4) Baiting characteristics







Total baits: 79,594 (78,016 fixed wing and 1,578 ground)
Bait density: 75 baits/km2
Flight line spacing: 750 meters
Off-time: 28% for fixed wing and 24% for ground using NLCD to determine “baitable”
habitat
Projected baiting dates: September 15-16, 2011
Baiting duration: 2 days, 1 plane and ground crews for hand-baiting

5) Bait-vaccine characteristics
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Each bait contains 1.8 ± 0.1ml of ONRAB® vaccine (titer of not < 109.5 cell culture
infectious dose 50% [CCID50]/ml)
Bait matrix is comprised of partially hydrogenated vegetable shortening (34%),
Microbond® wax (30%), stearine (12.5%), Icing sugar (20%), vegetable oil (1%),
artificial marshmallow flavor (1%), artificial sweet flavor (1%), and a fat-soluble food
dye (0.5%)
Bait matrix contains 100 mg of tetracycline hydrochloride as a biomarker
Each vaccine-bait weighs approximately 4g
The body of the blister pack is an elongated oval with dimensions of 1.81 x 0.55 x 0.39in
(30x14x10mm)
Each bait contains a conspicuous advisory label with a toll free number in the event of a
bait contact and potential vaccine exposure

6) Pre-ORV sampling (baselines)












Enhanced rabies surveillance has been in place for > than 1 year
Early baseline raccoon and skunk samples collected in 2010 from 5 density index sites
In late summer 2011, 150 raccoon-sized cage traps will be tended for 10 consecutive days
within each of the 4 buffered sampling cells
Traps will be deployed at random roadside trapping locations
Focus is to characterize target and non-target community
Expect capture rate at >100 raccoon/cell based on recent previous trapping efforts in area
Maximize skunk captures by additional targeted trapping if needed
Collect pertinent biological, physical and spatial-temporal data from live captured
raccoons and skunks and sera for rabies and human adenovirus serological analysis
Euthanize target species with unusual lesions or behaviors for pathological analysis
Late spring/summer 2011 collect nontarget tissue and sera from 5-day trapping studies
for serological and histopathological analysis
Implement continuous opportunistic sampling for target and nontarget species (e.g.,
roadkills) for histopathological analysis

7) Post-ORV sampling (treatment effects)






Continue enhanced rabies surveillance
Continue opportunistic sampling for target and nontarget species (e.g., roadkills, hunter
harvest) for histopathological analysis for up to 1 year post ORV
Upon completion of ORV collect buccal and anal swab samples and other pertinent
biological, physical and spatial-temporal data from target species for a 10-day period for
virus detection/isolation
Beginning 2 weeks post-ORV collect nontarget organ tissue and sera from 5-day trapping
studies for serological and histopathological analysis
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5 weeks post ORV sample ≥100 raccoons and as many skunks as practical within each of
the 4 buffered cells using the pre-ORV target species trapping protocol
Collect pertinent biological, physical and spatial-temporal data from raccoons and skunks
as well as sera for rabies and human adenovirus analysis
Monitor for abnormalities in captures/animals reported and collect samples as appropriate

8) Sample Analysis




Rabies virus serological titers to be determine by CDC
Human adenovirus titers potentially determined at Cornell
Histopathological analysis sources to be finalized

9) Captive pen safety studies at NWRC (separate protocol for review)


Species of concern: opossum, fox squirrel, wild turkey, cottontail and wood rats.

10) Report Findings



Expect results from analysis of field data by March 1, 2012
Draft report by May 1, 2012
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Appendix B: Post-ORV Sampling to Detect Human Adenovirus Serotype-5 as a Part of the
September 2011 ONRAB® Field Trial, Southeastern West Virginia
Trapping design and animal handling
Samples will be collected day 1 through day 6 to obtain buccal and anal swab samples from livetrapped target and non-target species for PCR and virus isolation. Fifty live traps should be set
the day of ONRAB® (Artemis Technologies, Guelph, Ontario, Canada) distribution within the
three intercellular spaces between the four sampling cells (Figure 1). This spatial trapping
design should minimize trap “happiness” or “shyness” within the raccoon and skunk populations
in the four sampling cells that will be trapped five weeks post-ORV. Traps should not be set in
buffer areas to eliminate edge effects.
All captured animals will be handled according to WS’ SOP used by the NRMP.
Swab sampling, processing and shipping
Swab samples will be collected from all target and non-target species captured during the first 6
days post-ORV using this design.
Once each live-trapped animal is anesthetized or in some cases euthanized (if warranted based on
signs or other factors), duplicate buccal and duplicate anal swab samples should be obtained
immediately using BD* Universal Viral Transport Kits (see vendor information under Supplies
at the end of this Appendix).
Thoroughly swab the inside of the mouth ensuring the each swab makes contact within the
mouth (e.g., tongue, roof, etc.). Place each swab into a properly labeled 1 mL viral media vial,
snap off the swab, properly seal each vial and immediately place on dry ice or in a freezer
(following vendor instructions). For anal swab samples, insert the swab into the anus the length
of the swab tip and gently complete one rotation and place each swab into the 1 mL viral media
as detail for buccal swabs. Place all swabs immediately on dry ice. Cooling quickly is a critical
step.
Each day (or every other day) samples should be sent by overnight mailed on dry ice to the
following address:
Dr. Edward Dubovi
Animal Health Diagnostic Lab
College of Veterinary Medicine
Upper Tower Road
Ithaca, NY 14853
607-253-3923
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An email with courtesy copy to Kathleen Nelson (knelson@aphis.usda.gov) should be sent to Dr.
Edward Dubovi(ejd5@cornell.edu) informing him that samples have been sent. Include an excel
spreadsheet with data and the UPS tracking number. Do not ship samples on Fridays unless
otherwise instructed to do so.
Recording data
If data collection is in MIS: Collect standard information for each capture, plus record time of
day each sample was collected. Time of sample collection/capture can be obtained by using the
time the animal was anesthetized from the PDA database file (dbf). The dbf file should be
retained to recall time of day for each capture, as this information is not uploaded to the MIS.
If data collection is outside of MIS: Collect data for the following fields: date, time of day,
latitude, longitude, species, sex, relative age, swab sample (yes or no), comments.
Supplies
BD* Universal Viral Transport Kits may be purchased at Fischer Scientific, catalog number: 22031-15.
http://www.fishersci.com/ecomm/servlet/fsproductdetail?storeId=10652&productId=13751252&
catalogId=29104&matchedCatNo=2203115&endecaSearchQuery=%23store%3DScientific%23
N%3D0%23rpp%3D15&fromSearch=1&searchKey=031||22||15&highlightProductsItemsFlag=
Y
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Appendix C: Materials and Methods Used in qPCR Screening of Human Adenovirus
Serotype-5 Rabies Virus Glycoprotein Recombinant Vaccine (ONRAB®)
Animal Health Diagnostic Center, Cornell University
January 19, 2012

Primers and probe for ONRAB® qPCR assay
The primers and probe sequences for the ONRAB® qPCR assay were from Knowles et al.
(2009a, 2009b). Primers were synthesized by Invitrogen and were purified by desalting. The
probe was sourced from Sigma Life Science and was HPLC purified.
AdRG-For

CAACTGTCCTAACCTTGGATTACATCA

HAd5 (upstream of rabies G)

AdRG-Rev

GAATTTCCCAAAACACAATGGAA

rabies G gene

AdRG-probe

FAM™-AGGCTCTCCTGTTTGTACCCCTTCTGGTT-BHQ®1

rabies G gene

Positive amplification control and assay verification
A positive amplification control (PAC) amplicon was generated using primers that flank the
assay target region.
Ad5E3-F GCGGACGGCTACGACTGAATGTTA
RVG-R

TTGTTTGGGCAGCTGAGGTGATGT

Vaccine was drawn directly from an ONRAB® bait and nucleic acid was extracted from a 200 µl
volume (Qiagen #69504). The PAC fragment was amplified from the purified DNA using a
commercially available PCR mix (Invitrogen, #11306-016) and a conventional thermocycler
(Stratagene Robocycler).
Cycling conditions were 94oC for 2 min, followed by 35 cycles of 94oC for 30 sec, an annealing
temperature for 30 sec, and 72oC for 1 min. The annealing temperature gradient included
reactions at 55oC, 57oC, 59oC and 61oC. Gel electrophoresis confirmed single bands in reactions
at all annealing temperatures. The reactions were pooled and purified (Qiagen #28106). The
purified PAC was quantified spectrophotometrically (Nanodrop 1000) and the copy number was
calculated.
An Applied Biosystems (ABI) Path-ID kit (#4388644) was used for PCR amplification. Forward
and reverse primers were used at a concentration of 400 nM and the probe was used at a
concentration of 120 nM. Four µl of the PAC dilution series, ranging from 1 × 107 copies /4 µl
to 1 × 10-1/4 µl, was used per reaction, in a total volume of 25 µl. Three initial test runs were
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conducted on a SmartCycler 2 thermocycler (Table 1 and Figure 1). Cycling conditions were
95oC for 10 min, followed by 40 cycles of 95oC for 15 sec, 60oC for 1 min. A subsequent run of
the PAC dilution series on an ABI 7500 thermocycler gave equivalent Ct values at each dilution
and an overall amplification efficiency of 101.8% (not shown). The PAC dilution amplification
series showed the assay to be consistently sensitive to a level of detection approximating 10
copies of viral DNA.
Table 1. Example summary of a run showing the Ct values of the PAC dilution series.

Run Summary
(Smart Cycler 2.0d)
Run NameOnRab Test 1 11-7-11
Started At
11/7/2011 16:42
Number o
10
Results Table
Site ID
Protocol
Sample ID
A1
PATH ID qPCR
ntc
A2
PATH ID qPCR
10^-1
A3
PATH ID qPCR
10^0
A4
PATH ID qPCR
10^1
A5
PATH ID qPCR
10^2
A6
PATH ID qPCR
10^3
A7
PATH ID qPCR
10^4
A8
PATH ID qPCR
10^5
A9
PATH ID qPCR
10^6
A10
PATH ID qPCR
10^7

Sample TNotes
UNKN
STD
STD
STD
STD
STD
STD
STD
STD
STD

Status
OK
OK
OK
OK
OK
OK
OK
OK
OK
OK

FAM Std/Res
ND

FAM Ct

0.1
1
10
100
1000
10000
100000
1000000
10000000
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0
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Figure 1.Upper panel shows the amplification plot of PAC dilution series. The lower panel shows the standard
curve generated from the data in Table 1 (Efficiency = 91.5%).

Purification and qPCR of samples
Swabs were received in universal viral transport tubes (Becton Dickinson, #220222) containing 3
ml of transport medium. Nucleic acid (NA) was purified from 175 µl of the medium using a
MagMax total Nucleic Acid Isolation Kit (ABI #1840). Purified NA was eluted in a final
volume of 50 µl.
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The ABI Path-ID mastermix (#4388644) was used for PCR amplification. Forward and reverse
primers were used at a concentration of 400 nM and the probe was used at a concentration of 120
nM. Four µl of purified NA was used per reaction in a total volume of 25 µl. The qPCR
reactions were run in 96-well plates on an ABI 7500 thermocycler. Cycling conditions were
95oC for 10 min, followed by 40 cycles of 95oC for 15 sec, 60oC for 1 min.
In addition to the test samples, each set of reactions included at least two negative control wells
(NTC), a positive extraction control (PEC) well with ONRAB® vaccine diluted at 1 × 10-5 in
transport medium, a negative extraction control (NEC) consisting of transport medium only, and
a PAC well with a calculated copy number of 100.
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Appendix D: Safety of ONRAB® in Select Captive Non-target Species
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Appendix E: Human Adenovirus Serotype-5 Titers Pre-ONRAB®
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Appendix F: Human Adenovirus Serotype-5 Titers Post-ONRAB®
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Appendix G: Histopathology Results from Captive Studies at Wildlife Services, NWRC
Dr. Kurt VerCauteren, Rabies Research Project Leader
ONRAB®, like Raboral V-RG®, is a recombinant vaccine. However, the viral vector in
ONRAB® is human adenovirus type 5 (Had5). Had5 is a relatively safe and well-studied virus,
which is used in many vaccine formulations. Wild-type Had5 often causes mild respiratory or
gastrointestinal manifestations in humans, although immunocompromised individuals may
develop a more serious disease (Textbook of Pediatric infectious diseases, Vol 2: Ralph Feigin).
Extensive studies on the efficacy and safety of the ONRAB® vaccine in animals have been
completed in Canada (Yarosh et al. 1996, Lutz-Wallace et al. 1995, Randrianarison-Jewthoukoff
and Perricaudet 1995, Rosette et al. 2009, Knowles et al. 2009), and the encouraging findings of
these studies initiated ONRAB’s distribution via aerial bait drop in 2006 targeting raccoons and
skunks. Rabies VNA seroconversion rates in areas baited with ONRAB® averaged 80% in the
first two years (Rosatte et al. 2009), well above the seroconversion rates when the vaccine
Raboral V-RG® is used (Slate et al. 2009, Brown et al. 2010).
For the non-target safety studies in the literature, researchers administered an ONRAB® dose 10
times the dose needed to vaccinate target species. Animals were monitored daily and all tolerated
exposure to the vaccine. Analyses of tissues resulted in viral RNA detected in some lung and
kidney samples. Following histopathological analysis, the most marked findings were in the
lungs with pulmonary congestion and some possible vaccine aspiration effects. Oral swabs
and/or fecal samples were collected from skunks, raccoons, fox, cotton rats, cats and dogs. Viral
shedding (if any) was generally complete by 4 days post-inoculation (dpi) except for one skunk,
which continued to shed virus in feces through 14 dpi (Knowles et al. 2009).
Our research expands on the species evaluated by Knowles et al. (2009) and investigates the
vaccine as it relates to its safety in wildlife species likely to come in contact with the ONRAB®
vaccine as part of WS NRMP ORV operations, as well as, identify whether Had5 shed from
certain wildlife species may increase the chance of humans contacting the Had5. As expected,
histological changes described in the non-target species vaccinated with ONRAB® (eastern
cottontails, fox squirrels, opossums and wild turkeys) are best attributed to common pathologic
changes in free-ranging wildlife. None of the histological findings in tissues of the study animals
appear to be related to the ONRAB® vaccine (Table 1).
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Table 1. A summary of histological findings unrelated to vaccination by ONRAB® are summarized by species.
Species

n

Vaccinates

Non-vaccinates

Cottontail Rabbit (Sylvilagus floridanus)
Eastern Wild Turkey (Meleagris gallopavo silvestri)
Virginia Opossum (Didelphis virginiana)
Fox Squirrel (Sciurus niger)

16
23
19
23

14
21
17
21

2
2
2
2

Cottontail rabbits: The most common finding in the cottontails (n=16), both vaccinates and nonvaccinates, was the presence of tapeworms in the gastrointestinal tract. Parasites were observed
on both gross and histologic examination in 12/16 animals; histologically there was often a very
mild increase in the number of lymphocytes and plasma cells in the lamina propria of infected
animals. In the liver of two vaccinated animals there were areas of inflammation, regionally
extensive and histiocytic with multinucleated giant cells in one animal and a focal granuloma
with fibrosis in another animal that was presumed to be secondary to parasite migration. A
degenerate parasite was identified within the center of the granuloma. Very mild, patchy
interstitial nephritis was observed in two cottontails and lymphoplasmacytic aggregates in portal
areas of the liver were seen in 5 cottontails, both vaccinates and non-vaccinates. One cottontail
had a small focus of inflammation in the lung while another had some mild bronchiole associated
lymphoid tissue (BALT) hyperplasia. Findings in the large intestine or spleen of all cottontails
were unremarkable. Histological variation described for cottontail rabbits are presumably
unrelated to vaccination with the ONRAB® vaccine.
Fox Squirrels: The most significant changes in fox squirrels (n=23) were observed in the
kidneys of both the vaccinated and non-vaccinated animals. Sixteen fox squirrels, both
vaccinates and non-vaccinates, had some degree of inflammation in the interstitum of the kidney
that ranged from mild and patchy to very severe and regionally extensive. In five animals (4
vaccinates, 1 non-vaccinate) suppurativetubulitis was also observed, possibly a result of naturally
acquired leptospirosis infection. In the liver of fourteen fox squirrels, including both vaccinates
and non-vaccinates, there were small aggregates of lymphocytes and plasma cells in portal areas.
Mild bronchial associated lymphoid tissue hyperplasia was seen in the lung of 4/23 animals with
no apparent cause (1 non-vaccinate, 3 vaccinates). A single fox squirrel had a small focus of
acute inflammation in the lung. Mild, patchy increases in lymphocytes and plasma cells were
seen in the small or large intestine of three fox squirrels (1 non-vaccinate, 2 vaccinates).
Histological variation described for fox squirrels are presumably unrelated to vaccination with
the ONRAB® vaccine.
Opossums: On gross examination of opossums (n=19) multiple metazoan parasites were seen
throughout the gastrointestinal tracts of nearly all opossums. Histologically there were numerous
eosinophils as well as lymphocytes and plasma cells in the small intestine of all opossums
(vaccinates and non-vaccinates), but fewer inflammatory cells were present in the colon. On
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gross examination, the livers of all opossums were mildly enlarged and fatty on palpation.
Histologically fatty change was seen most commonly in centrilobular areas, but panlobular in
many animals. Inflammation similar to that seen in the gastrointestinal tract (eosinophillic to
mixed infiltrate) was observed in portal areas of the liver of 14 opossums (2 non-vaccinates, 12
vaccinate) and ranged from very mild to moderate. Mild interstitial, lymphoplasmacytic
inflammation was seen in the kidney of 11 opossums (2 non-vaccinates, 9 vaccinates) and
mineralization was identified in the collecting tubules of 2 (both vaccinates) opossums. A single
animal had a moderate amount of interstitial inflammation that also included eosinophils and
there was some mild, secondary tubular distortion. Foci of mineralization were identified in the
lung of 8 animals (2 non-vaccinates, 6 vaccinates). Mineral was usually devoid of associated
reaction however foci of inflammation were identified in 10 animals (2 non-vaccinate, 8
vaccinates). Inflammatory change ranged from small foci of foamy macrophages and
lymphocytes, to a single opossum with a mineralized granuloma and a single opossum with a
large protazoal cyst surrounded with mixed inflammation (non-vaccinate). Airway associated
lymphoid tissue was often hyperplastic and contained amyloid. Histological variation described
for opossums are presumably unrelated to vaccination with the ONRAB® vaccine.
Wild Turkeys: The most significant histologic change observed in the wild turkeys (n=23) was a
variable amount of extramedullaryhematopoesis in multiple tissues. Change was most notable in
the liver (2 non-vaccinates, 13 vaccinates) but also present in the intestinal tract and the lung
(five turkeys, all vaccinates). Dust granulomas were seen in the lungs of six birds. Two
vaccinated turkeys had small foci of heterophillic inflammation in the kidneys and three had
notable extra medulla hematokinesis. Histologic changes were uncommon in the gastrointestinal
tract; extra medulla hematokinesis was variable and a single turkey had a focal, small crypt
abscess in the gastrointestinal tract. Histological variation described for wild turkeys are
presumably unrelated to vaccination with the ONRAB® vaccine.
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